Case report: CD19-directed CAR-T cell therapy combined with BTK inhibitor and PD-1 antibody against secondary central nervous system lymphoma

被引：3
作者：
Zhang, Wenqi [1 ]
Huang, Chen [1 ,2 ]
Liu, Ruixia [1 ]
Zhang, Huichao [3 ]
Li, Weijing [1 ]
Yin, Shaoning [1 ]
Wang, Lianjing [1 ]
Liu, Wei [1 ]
Liu, Lihong [1 ,2 ]
机构：
[1] Hebei Med Univ, Hosp 4, Dept Hematol, Shijiazhuang, Peoples R China
[2] Hebei Prov Key Lab Tumor Microenvironm & Drug Resi, Shijiazhuang, Peoples R China
[3] Hebei Med Univ, Hosp 4, Clin Lab, Shijiazhuang, Peoples R China
来源：
FRONTIERS IN IMMUNOLOGY | 2022年 / 13卷
关键词：
scnsl; CD19 CAR-T cell therapy; BTK inhibitor; PD-1; antibody; zanubrutinib; tislelizumab; EFFICACY;
D O I：
10.3389/fimmu.2022.983934
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Current therapeutic strategies for central nervous system (CNS) relapse of diffuse large B-cell lymphoma (DLBCL) are extremely limited. Secondary central nervous system lymphoma (SCNSL) also shows a grave prognosis and high mortality. This report describes a young female patient with DLBCL and CNS relapse who received low-dose CD19-directed chimeric antigen receptor T (CAR-T) cell therapy followed with Bruton's tyrosine kinase inhibitor and programmed cell death protein 1 antibody after several lines of chemotherapy. However, limited reports on CAR-T cell therapy are applied for SCNSL, particularly those in combination with targeted agents. The current treatment combination for this case provides a new regimen for CNS relapse from DLBCL.
引用
收藏
页数：8
相关论文
共 33 条
  • [11] CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma
    Heczey, Andras
    Louis, Chrystal U.
    Savoldo, Barbara
    Dakhova, Olga
    Durett, April
    Grilley, Bambi
    Liu, Hao
    Wu, Mengfeng F.
    Mei, Zhuyong
    Gee, Adrian
    Mehta, Birju
    Zhang, Huimin
    Mahmood, Nadia
    Tashiro, Haruko
    Heslop, Helen E.
    Dotti, Gianpietro
    Rooney, Cliona M.
    Brenner, Malcolm K.
    [J]. MOLECULAR THERAPY, 2017, 25 (09) : 2214 - 2224
  • [12] CRISPR/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions
    Hu, Wanghong
    Zi, Zhenguo
    Jin, Yanling
    Li, Gaoxin
    Shao, Kang
    Cai, Qiliang
    Ma, Xiaojing
    Wei, Fang
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (03) : 365 - 377
  • [13] Mechanisms of failure of chimeric antigen receptor T-cell therapy
    Li, Xiaoqing
    Chen, Weihong
    [J]. CURRENT OPINION IN HEMATOLOGY, 2019, 26 (06) : 427 - 433
  • [14] Synergistic effect of ibrutinib and CD19 CAR-T cells on Raji cells in vivo and in vitro
    Liu, Meijing
    Wang, Xuelin
    Li, Zheng
    Zhang, Rui
    Mu, Juan
    Jiang, Yanyu
    Deng, Qi
    Sun, Lei
    [J]. CANCER SCIENCE, 2020, 111 (11) : 4051 - 4060
  • [15] Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
    Locke, Frederick L.
    Neelapu, Sattva S.
    Bartlett, Nancy L.
    Siddiqi, Tanya
    Chavez, Julio C.
    Hosing, Chitra M.
    Ghobadi, Armin
    Budde, Lihua E.
    Bot, Adrian
    Rossi, John M.
    Jiang, Yizhou
    Xue, Allen X.
    Elias, Meg
    Aycock, Jeff
    Wiezorek, Jeff
    Go, William Y.
    [J]. MOLECULAR THERAPY, 2017, 25 (01) : 285 - 295
  • [16] Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
    Maude, Shannon L.
    Frey, Noelle
    Shaw, Pamela A.
    Aplenc, Richard
    Barrett, David M.
    Bunin, Nancy J.
    Chew, Anne
    Gonzalez, Vanessa E.
    Zheng, Zhaohui
    Lacey, Simon F.
    Mahnke, Yolanda D.
    Melenhorst, Jan J.
    Rheingold, Susan R.
    Shen, Angela
    Teachey, David T.
    Levine, Bruce L.
    June, Carl H.
    Porter, David L.
    Grupp, Stephan A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (16) : 1507 - 1517
  • [17] PD-1 disrupted CAR-T cells in the treatment of solid tumors: Promises and challenges
    McGowan, Eileen
    Lin, Qimou
    Ma, Guocai
    Yin, Haibin
    Chen, Size
    Lin, Yiguang
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2020, 121
  • [18] Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
    Mhibik, Maissa
    Wiestner, Adrian
    Sun, Clare
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (01)
  • [19] Programmed cell death protein-1 inhibitor combined with chimeric antigen receptor T cells in the treatment of relapsed refractory non-Hodgkin lymphoma: A case report
    Niu, Zhi-Yun
    Sun, Li
    Wen, Shu-Peng
    Song, Zheng-Rong
    Xing, Lina
    Wang, Ying
    Li, Jian-Qiang
    Zhang, Xue-Jun
    Wang, Fu-Xu
    [J]. WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (10) : 2394 - 2399
  • [20] NK Cells Expressing a Chimeric Activating Receptor Eliminate MDSCs and Rescue Impaired CAR-T Cell Activity against Solid Tumors
    Parihar, Robin
    Rivas, Charlotte
    Mai Huynh
    Omer, Bilal
    Lapteva, Natalia
    Metelitsa, Leonid S.
    Gottschalk, Stephen M.
    Rooney, Cliona M.
    [J]. CANCER IMMUNOLOGY RESEARCH, 2019, 7 (03) : 363 - 375
1234